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Abstract
Genome-editing nucleases like the popular CRISPR/Cas9 enable the generation of knock-
out cell lines and null zygotes by inducing site-specific double-stranded breaks (DSBs) 
within a genome. In most cases, when a DNA template is not present, the DSB is repaired 
by nonhomologous end joining (NHEJ), resulting in small nucleotide insertions or dele-
tions that can be used to construct knockout alleles. However, for several reasons, these 
mutations do not produce the desired null result in all cases, instead generating a similar 
protein with functional activity. This undesirable effect could limit the therapeutic effi-
ciency of gene therapy strategies focused on abrogating oncogene expression by CRISPR/
Cas9 and should be taken into account. This chapter reviews the irruption of CRISPR 
technology for gene silencing and its application in gene therapy.
Keywords: gene therapy, knockout, null allele, oncogene silencing, CRISPR technology, 
gene suppression
1. Gene suppression therapies in cancer: an overview
Gene therapy, which was initially developed for the treatment of genetic (primarily mono-
genic) diseases, has mainly focused on cancer therapy, so that more than 65% of all gene 
therapy trials worldwide (Figure 1) are aimed at the treatment of solid and hematological 
malignancies [1]. As a consequence, cancer gene therapy is a predominant field of basic 
research, as well as of clinical activities (Table 1) [2].
Various strategies at different molecular levels (Figure 2) have been employed to treat malig-
nant diseases in recent decades, such as specific drug inhibitors acting at the protein level, 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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gene suppression therapies at the mRNA level, and genome-editing nucleases at the DNA 
level [3].
The ability of several drugs to inhibit the activity of a targeted oncoprotein has been exploited 
as a therapeutic approach for a variety of malignancies, the best example being imatinib 
mesylate, a tyrosine-kinase inhibitor (TKI) indicated for the first-line treatment of chronic 
myeloid leukemia (CML). The advent of imatinib mesylate at the end of the twentieth century 
has revolutionized CML prognosis, yielding an overall survival (OS) rate of 88% after 5 years, 
whereas previous nonspecific treatments produced an OS rate of only 57% [4]. Unfortunately, 
despite the increased efficacy and better clinical responses, many patients receiving targeted 
drugs have a poor initial response, develop resistance, or undergo relapse after initial success. 
Except for a subgroup of patients who achieve a deep and sustained molecular response, TKI 
Figure 1. Gene therapy trials worldwide.
Indications Gene therapy clinical trials
Number %
Cancer diseases 1688 65.0
Cardiovascular diseases 180 6.9
Gene marking 50 1.9
Healthy volunteers 56 2.2
Infectious diseases 182 7.0
Inflammatory diseases 15 0.6
Monogenic diseases 287 11.1
Neurological diseases 47 1.8
Ocular diseases 34 1.3
Others 58 2.2
Table 1. Gene therapy trials worldwide.
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therapies would need to be continued indefinitely because TKIs do not completely eliminate 
the leukemia stem cells (LSCs), but they remain even during effective TKI treatment [5].
An alternative oncoprotein inhibition approach emerges from the ability of some small RNAs 
to fold into three-dimensional structures that can then bind to proteins and thereby inhibit 
them in a manner similar to protein antagonists [6]. This is the logic behind the use of RNA 
“decoys” or RNA aptamers. Recent preclinical and clinical data support the potential activ-
ity of a 45-nucleotide-long RNA aptamer (NOX-A12) that specifically antagonizes the CXC 
chemokine ligand 12/stromal cell-derived factor-1 (CXCL 12/SDF-1), which is a regulatory 
chemokine essential for the migration of leukemic stem cells into the bone marrow [6]. This 
inhibition of the binding of SDF-1 to its receptors can prompt the leukemic stem cells to re-
enter the cell cycle and become vulnerable to chemotherapeutic attack.
Other gene suppression therapies focus on the intervention of gene transcription and trans-
lation, which are vital elements for cancer growth, spread, survival, and therapy resistance. 
Ribozymes, antisense oligodeoxynucleotides (AS-ODNs), and short-interfering RNAs (siRNAs) 
are an emerging class of targeted DNA-based pharmaceuticals. Ribozymes, a subset of catalytic 
RNAs, can be artificially synthesized and used to specifically suppress gene function. They can 
also be used to validate disease-related genes as potential targets for new therapeutic interven-
tions. Their ability to cleave mRNA to prevent protein synthesis enables them to be applied in 
cancer and virology. Transcripts of genes of different function have been targeted by AS-ODN 
gene therapies such as c-myb, c-raf, c-fos, H-ras, Her2/neu, bcl-2, VEGF, and Ang-1. The use 
Figure 2. Different strategies to block oncogene effects.
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of AS-ODNs was shown to successfully inhibit gene expression in association with tumor 
growth inhibition, radiosensitization, or chemosensitization [7–9]. The use of siRNA technol-
ogy provides another novel approach for targeted sequence-specific suppression of target gene 
expression. In this system, siRNA stability and proper delivery are key factors for successful 
application. In vitro and in vivo studies with siRNA targeting PKN3 mRNA have been successful 
at inhibiting tumor progression and metastasis in lung and mammary carcinoma models [10]. 
Nonetheless, inefficient/complete silencing and transient effects present major challenges to can-
cer gene therapy mediated by ribozymes, AS-ODNs, or siRNAs [2]. Other important challenges 
that need to be addressed for the successful translation of these approaches are their delivery to 
the site of action, the choice between direct delivery or the use of a vehicle, mass production at 
low cost, more clearly defined pharmacokinetics, and the ability to produce sustained long-term 
effects, immunogenicity, and toxicity (including inappropriate or excessive expression).
With the recent explosion of genome editing tools, including clustered, regularly interspaced 
short palindromic repeats and their nuclease-associated protein Cas9 (CRISPR/Cas9), the land-
scape of suppression techniques has dramatically changed. Although CRISPR/Cas9 is similar in 
action and efficacy to protein-based targeted nucleases, such as zinc finger nucleases (ZFNs) and 
transcription activator-like effector nucleases (TALENs) [11], the ease with which these reagents 
can be designed and tested through the construction of single-guide RNAs (sgRNAs) has made 
gene editing available to a wider variety of users and for a broader range of applications.
CRISPR/Cas9 works at the DNA level and has the advantage of providing permanent and 
full gene knockout, while AS-ODNs and siRNAs only silence genes transiently because they 
working at the mRNA level [12, 13]. CRISPR/Cas9 cuts DNA in a sequence-specific manner 
with the possibility of interrupting coding sequences, thereby making it possible to turn off 
cancer drivers in a way that was not previously feasible in humans [14, 15]. This notable 
application of permanent gene disruption is based on the cellular mechanisms involved in 
double-stranded break (DSB) repair.
2. CRISPR-Cas9 technology, DSBs, and gene interruption
The CRISPR/Cas9 system allows sequence-specific gene editing in many organisms and is 
currently the best tool for generating cell lines and animal models of human diseases. The 
main advantages of this technology are its simplicity, versatility, and efficiency compared 
with other gene-modifying technologies. CRISPR/Cas9 technology is usually used to intro-
duce targeted DSBs in any biological system [16], and the only requirement for Cas9-mediated 
DNA recognition and cleavage is the presence of a short protospacer adjacent motif (PAM) 
immediately 3′ to the targeted DNA sequence [17] (Figure 3).
Following the creation of a DSB within the coding sequence of a gene, mechanisms of DNA 
repair can induce insertions and deletions (indels), resulting in frameshift or nonsense muta-
tions [18]. Basically, the repair of DSBs involves four possible mechanisms (Figure 4). The first 
mechanism is standard nonhomologous end-joining (C-NHEJ). In this mechanism, the DSB is 
repaired by blunt-end ligation independently of sequence homology and requires DNA ligase 
IV action (Figure 1A). C-NHEJ can occur throughout the cell cycle but is dominant in G0/G1 
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and G2 and is associated with 1–4 bp deletions [19], which could produce frameshift mutations. 
Alternatively, the DSB end can be resected, leaving 3′ single-stranded DNA (ssDNA) overhangs. 
The resected DSB can be repaired by three possible mechanisms: homologous recombination 
(HR), single-strand annealing (SSA), and alternative end joining (alt-EJ). HR predominates in 
Figure 3. CRISPR/Cas9 ribonucleoprotein complex. Cas9 nuclease is driven to the target DNA sequence by an sgRNA 
molecule, composed by crRNA (blue) and trackRNA (green). The target sequence must be followed immediately by 
a protospacer adjacent motif sequence (PAM). After hybridization of 20 nt of the cRNA with the target sequence, the 
nuclease performs a double-stranded break 3 nt upstream of the PAM sequence.
Figure 4. Approaches to repair DNA double-strand breaks. When DNA resection is blocked, C-NHEJ (classic 
nonhomologous end joining) is well established, whereas if the resection does occur, DNA damage is repaired by HR 
(homologous recombination), SSA (single-strand annealing) or alt-EJ (alternative end joining) [18].
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the mid-S and mid-G2 cell cycle phases, where the amount of DNA replication is highest and 
when the sister template is available [20]. HR uses a template for repair and so requires strand 
invasion mediated by the recombinase RAD51 (Figure 4) [21]. It may be possible to exploit 
this property to edit mutations, delivering the appropriate template joined to the CRISPR/Cas9 
system inside the target cell. The resected DSB can also be repaired by mutagenic repair path-
ways, namely SSA or alt-EJ. SSA mediates end joining between interspersed nucleotide repeats 
in the genome and involves reannealing of Replication Protein A (RPA)-covered ssDNA by the 
RAD52 protein. SSA is typically associated with large deletions (Figure 4) [21]. The alt-EJ mech-
anism is not well understood but has an apparent predilection for joining DSBs on different 
chromosomes, thereby generating chromosomal translocations and mutagenic rearrangements 
(Figure 4) [22]. Early evidence for alt-EJ came from studies, showing that yeast and mammalian 
cells deficient in C-NHEJ were still able to repair DSBs via end joining [23].
As a consequence of its efficiency at inducing DSB, CRISPR/Cas9 technology has gained a 
reputation as the “gold standard” for creating null alleles in both in vivo and in vitro. These 
null alleles can arise from frameshift mutations, premature stop codons, and/or non-sense-
mediated decay on the target gene, resulting in loss of function. Currently, CRISPR/Cas9 is 
extensively used to engineer gene knockouts, but due to the variable size of the NHEJ-induced 
indel, generating a full KO in one step is not always achieved. In fact, full KO generation 
requires off-frame mutations in both alleles, and this is a matter of probability because several 
mutations could preserve the reading frame (e.g., +3 or −3 mutations). This undesirable effect 
Figure 5. Experimental design of the first CRISPR/Cas9-edited cell injection in humans. Immune precursor cells were 
isolated from blood and in vitro CRISPR/Cas9 edited to eliminate PD-1 gene. Modified cells were then reinfused into 
the patient [25].
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may be irrelevant in assays in which the knockout cell can be selected, or the null allele of the 
animal model can be segregated [24]. The first clinical trial using CRISPR for gene suppres-
sion and cancer therapy enrolled its first patient at Sichuan University’s West China Hospital 
in Chengdu in 2016 [25]. In this study, the safety of PD-1 knockout CRISPR-engineered T 
cells ex vivo was evaluated when treating metastatic non–small cell lung cancer that had pro-
gressed after employing all standard treatments. Patients enrolled in the gene-editing trial 
provided peripheral blood lymphocytes, and PD-1 knockout of T-cells by CRISPR/Cas9 was 
performed ex vivo. In this trial, the edited lymphocytes were selected, expanded, and subse-
quently infused back into the patients (Figure 5).
Nevertheless, there are several situations, either in vivo or in vitro, where cell selection and 
expansion are not an option, and obtaining a high knockout/gene inactivation efficiency is 
crucial [26, 27]. Hematological cancer therapies based on specific oncogenic silencing within 
primitive pluripotent stem cells could be the best example of these situations. In this patho-
logical cell context, the highly efficient interruption of the oncogenic open reading frame 
(ORF) could be an effective therapeutic option. It would even be more important for those 
tumors directed by a single oncogenic event, as is the case for several leukemias or sarcomas, 
which are directed by specific fusion oncoproteins [28, 29].
3. CRISPR-Cas9 technology for disrupting fusion oncogenes
Fusion oncoproteins arising from chromosomal rearrangements are known to drive the patho-
genesis of a variety of hematological neoplasms such as CML, which results from a reciprocal 
translocation between chromosome 9 and 22 [30, 31]. This translocation fuses the ABL1 gene 
on chromosome 9 to the BCR gene on chromosome 22, resulting in a BCR/ABL fusion gene, 
whose product is a cytoplasmic 210-KDa protein with upregulated tyrosine kinase activity 
that is considered essential for growth and survival of the leukemic cells [32]. As we previ-
ously mentioned, the discovery of BCR-ABL-mediated pathogenesis of CML provided the 
insight for the design of an inhibitory agent that targets BCR/ABL kinase activity such as 
imatinib mesylate. However, a substantial proportion of CML patients may not achieve the 
desired response or may eventually fail to respond adequately to these drugs [4]. A recent 
study of the BCR/ABL oncogen showed this gene fusion to be an ideal target for CRISPR/
Cas9-mediated gene therapy. A CRISPR-Cas9 application truncated the specific BCR-ABL 
fusion (p210) in an in vitro cellular model [15] (Figure 6).
In this study, a nontumorigenic cell line (BaF3), which needs IL-3 to survive and proliferate 
[33], was transformed with the fusion oncogene BCR/ABLp210 (BaF3-p210). The human 
BCR/ABL oncogenic fusion confers on BaF3 the ability to survive and proliferate in the 
absence of IL-3 and forms tumors in a xenograft model. Three custom-designed sgRNAs 
were used to genetically inactivate the BCR/ABL oncogene. These specific sgRNAs directed 
Cas9 to the BCR/ABL fusion sequence (Bcr-Abl sgRNA) or to the Abelson tyrosine kinase 
sequence (Tk-Abl 1 sgRNA and Tk-Abl 2 sgRNA) (Figure 7). Lentiviral infection assays were 
performed with each CRISPR/Cas9 reagents to generate three different BaF3-p210 cell lines 
with the potentially edited BCR/ABL oncogene at the expected cleavage point in each one.
CRISPR-ERA for Switching Off (Onco) Genes
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The CRISPR/Cas9 system efficiently induced various mutations at the expected cleavage 
point, giving rise to three distinct BaF3-p210 cell lines (CRISPR-BaF3-p210) with several 
altered BCR/ABL sequences.
As a result, significantly more cell death was observed in all CRISPR-BaF3-p210 cell lines in 
the absence of IL-3 than in BaF3 parental cells or mock BaF3-p210 cells (Figure 8).
Xenograft experiments were carried out to determine whether the tumorigenic capacity 
was also blocked by the action of the CRISPR/Cas9 system. Mice injected with the three 
Figure 7. Schematic representation of BCR/ABL fusion transgene. Sequences of sgRNAs designed to edit fusion region 
(red boxes). One of them hybridizes at the BCR/ABL junction, and the other two hybridize in exon 2 of ABL [15].
Figure 6. Experimental model to show the ability of CRISPR/Cas9 to truncate BCR/ABL fusion. The non-tumorigenic 
and IL-3-dependent BaF3 cell line was transformed with fusion oncogene BCR/ABLp210. The transformed cell line is 
able to grow and survive in the absence of IL-3, although the cells enter into apoptosis when CRISPR/Cas9 introduces 
mutations in the sequence of the BCR/ABL oncogene, preventing its expression [15].
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CRISPR-BaF3-p210 cell lines gave rise to significantly smaller subcutaneous tumors than 
those produced by the nonedited cells (Figure 9).
As expected, these small tumors were composed of nonedited cells, edited cells with +3/−3 bp 
indels (or multiples), or cells with nonframeshift mutations. This result indicated that a spe-
cific cellular selection or more specific sgRNAs should be necessary before potential gene 
Figure 8. Functional analysis of CRISPR-BaF3-p210-edited cells. Annexin V labeling was measured by flow cytometry 
in edited cells (BCR-ABL, TK-ABL1 and TK-ABL-2) in the presence and absence of IL-3. When IL-3 was removed from 
the medium, the three cell lines showed an increase in apoptosis, reflecting the absence of expression of the BCR-ABL 
oncogene [15].
Figure 9. In vivo effects of CRISPR-mediated editing of BCR/ABL oncogene. Tumor growth over 24 days following 
subcutaneous cell injection. The final tumor mass was reduced by half in the CRISPR-BaF3-p210, relative to controls. 
CRISPR-BaF3 single cell-derived cell line (SC) cells were unable to form a subcutaneous tumor [15].
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therapy in human. For this purpose, a CRISPR-BaF3-p210 cell line derived from a single cell 
(CRISPR-BaF3-p210-SC) carrying an 8-bp deletion (Figure 9) was selected to test tumorigenic 
capacity. No tumor growth was observed in any mouse injected with cells derived from the 
single-edited cell line (Figure 9).
3.1. CRISPR/CAS9 and knocking out genes in mouse
An option to improve knockout effectiveness could be to use two or more RNA guides at 
the same time to knock out the oncogene allele at different key sites in an attempt to try to 
guarantee the null result. This approach is commonly used for knocking out genes in animal 
models such as mice. Using two sgRNA guides makes it possible to distinguish the mutant 
pups by a simple PCR. An example of this is the generation and genetic characterization of 
Six6os1-deficient mice [34] (Figure 10).
Unfortunately, the possibility of using several RNA guides at the same time is quite limited 
in gene therapy, especially when adeno-associated virus vectors are used. The main difficulty 
stems from the limitations on the construct, for which reason other Cas9 orthologues are being 
used to introduce the nuclease coding sequence, one promoter and a single RNA guide [26, 35].
3.2. CRISPR/Cas9 delivery and gene therapy
The CRISPR/Cas9 complex can be introduced into cultured cells and single-cell embryos in 
the form of DNA, RNA, or protein [36]. The DNA encoding Cas9 and gRNA can be delivered 
into the cell using plasmid and viral expression vectors. RNA or protein has been introduced 
through microinjection, liposome-mediated transfection, electroporation, and nucleofection. 
Figure 10. Schematic representation of Six6os1 WT and edited allele. Two sgRNAs were used to produce a deletion 
between exon 2 and 3. As a consequence, a premature stop codon appears at the beginning of exon 3. The edited allele 
can easily be detected by PCR [34].
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However, the delivery formats of mRNA and protein pose certain technical challenges in vivo 
and viral-based in vivo genome editing remain a popular choice for achieving the stable or 
elevated expression of Cas9 and its sgRNA [37].
Given the great potential of viral vectors in gene and cell therapy, five major classes of viral 
vectors—retroviruses [38], lentiviruses [39, 40], adenoviruses [41, 42], AAVs [43, 44], and 
baculoviruses [45, 46]—have been used to deliver CRISPR components into mammalian cells 
for targeted genome editing. The advantages and disadvantages of using these viral vectors 
for in vivo delivery of the CRISPR transgenes have been extensively reviewed [43, 47–49]. In 
Table 2, we list the general characteristics and applications of various viral delivery vectors.
Currently, adenoviral vectors and γ-retroviruses are the most commonly used delivery system 
in gene therapy (Figure 11; Table 3) [1]. For Cas9 delivery, adenovirus (ad)- and retro/lentivirus 
(rt/lt)-based vectors have the advantage of packaging sizes of up to 30 kb (ad) and 7 kb (rt/lt), 
allowing the accommodation of the SpCas9 gene (∼4.2 kb), one or more sgRNAs, and the cis-
acting regulatory sequences required for efficient expression. Nevertheless, several disadvantages 
such as low titers (rt/lt), insertional oncogenesis (rt/lt), generation of a replication-competent len-
tivirus (rt/lt), immunogenicity, and toxicity (ad) are risks that should be taken account in in vivo 
gene therapy.
In contrast, the AAV system has major advantages for research and therapeutics, including 
very low immune response and toxicity. AAVs remain in the cell as episome, avoiding inser-
tional mutagenesis by random integration into the host genome. In fact, there are no human 
diseases related to them, and they can exist long term as concatemers in nondividing cells for 
stable transgene expression [50]. Given this, AAV is thought to be one of the most suitable viral 
vectors for gene therapeutic applications and gene transfer in vivo. However, two limitations 
restrict its use: packing size and tropism. AAV has a packaging capacity of only ∼4.8 kb. This 
makes it impossible to express the ∼4.2-kb SpCas9 gene and the sgRNA from a single AAV 
vector. One approach is to use two AAV vectors: one to express SpCas9 and the other to encode 
one or more sgRNAs [44]. A second approach is to use a different smaller Cas9, for example, 
the ∼3.2-kb Cas9 gene encoded by Staphylococcus aureus (SaCas9) [35, 51]. In this sense, single 
Guide Editing efficiency (%) TIDE-predicted indels
Bcr-Abl sgRNA 85.0 +1 bp (17.5%), −1 bp (9.1%), −2 bp (4.8%)
−3 bp (3.4%), −4 bp (6%), −6 bp (1.8%),
−8 bp (18.9%), −11 bp (10.2%), −18 bp (5.1%)
TK-ABL 1 sgRNA 54.6 +1 bp (14.9%), −1 bp (8%)
−2 bp (5.2%), −10 bp (17.6%)
TK-ABL 2 sgRNA 68.8 +1 bp (30.8%), −1 bp (5.9%), −2 bp (4.8%),
−4 bp (15.2%), −14 bp (5.1%)
Mock sgRNA 0.0
Table 2. Indels induced by each sgRNA predicted by the TIDE algorithm.
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Characteristics of 
a typical vector
Retrovirus Lentivirus Adenovirus Adeno-associated 
virus
Baculovirus
Common viral 
type
γ-retroviruses HIV-1 Ad5 AAV2 AcMNPV
Viral genome 
structure
Linear ssRNA Linear ssRNA Linear dsDNA Linear ssDNA Circular dsDNA
Viral genome size 8.3 kb 9.7 kb 36 kb 4.7 kb 80–180 kb
Packaging 
capacity
<8.0 kb <8.0 kb <30 kb <4.5 kb >38 kb
Cells infected Dividing Dividing or 
nondividing
Dividing or 
nondividing
Dividing or 
nondividing
Dividing or 
nondividing
Transduction 
efficiency
Moderate High Very high High High
Transgene 
expression
Stable Stable Transient Transient Transient
Immune response Moderate Low High Very low Very low
Toxicity High Moderate High Low Low
Random genome 
integration
Yes Yes No Generally, no 
(recombinant 
AAV has a low 
frequency of 
host genome 
integration events)
No
Common 
applications
Generating 
stable cell and 
gene transfer, 
cancer and stem 
cell research
Transduce 
difficult-to-
transfect cell, 
genome-wide 
screens
Vaccine 
production, 
cancer-immune 
therapy
Gene delivery in 
vivo, optogenetics
Recombinant 
proteins and vaccine 
production
Clinical trials Very popular Very popular Popular Increasingly 
popular
Growing interest
Table 3. Viral delivery systems most commonly used in gene therapy.
Figure 11. Delivery systems commonly used in gene therapy clinical trials.
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AAV vectors are able to express SaCas9, and one sgRNA has been described that appears to 
be potentially very useful for in vivo gene editing. A single AAV vector with U6-driven sgRNA 
and a TBG-driven SaCas9 expression cassette was used to target the cholesterol regulatory 
gene Pcsk9 in mouse liver. In this study, the authors observed modification in >40% genes, 
accompanied by significant reductions in serum Pcsk9 and total cholesterol levels [35].
Another problem with AAV vectors is their limited tissue tropism, although this has gradu-
ally expanded with the identification of additional AAV variants from different species and 
the derivation of AAV recombinants with enhanced tropism for specific tissues [52, 53]. AAV 
serotypes with a strong tropism for hepatocytes, neurons, and epithelial and endothelial cells 
have been described, but the search for AAV variants that can efficiently infect HSC or lym-
phoid cells has yet to identify any candidates [54].
All these advantages have led to increases in the number of studies using AAV vectors to 
deliver the CRISPR components in animals and in clinical trials for gene therapy.
3.3. CRISPR-Cas9 sgRNAs: “Superguides” for interfering with (onco)gene 
expression
When a cancer cell is the target, a delivery strategy that can result in the expression of Cas9 
and an oncogen-specific sgRNA in all infected cells is desirable. This is especially critical for in 
vitro gene therapy where the expansion processes from a selected edited cell are not available. 
Similarly, it is also crucial for in vivo approaches in cancer therapies focused on disrupting a 
driver oncogene. If the efficiency of CRISPR/Cas9 reagents delivery to the cancer cell is accept-
able, the key step for success lies in the effectiveness of a specific sgRNA at knocking out the 
oncogene. In this way, for the vast majority of knockout studies where the edited cells or 
mice can be selected, the sgRNA targets different positions within the chosen exon, avoiding 
boundaries. In most of these cases, the designs follow off-target criteria. However, for all those 
cases where cellular selection is not an option and only one sgRNA can be used, the null effect 
could be increased with a sgRNA targeting the exon boundary. Following this strategy, the 
generation of null alleles would be increased by two ways: probability of producing a frame-
shift mutation and probability of breaking the canonical pre-mRNA splicing (Figure 12).
It has long been known that mutations in splice-site consensus sequences can affect pre-mRNA 
splicing patterns and can lead to generate null or deficient alleles [55]. In fact, pioneering genetic 
studies indicated that many of the thalassemia mutations in the β-globin gene affect splice 
sites and give rise to aberrant splicing patterns [56, 57]. Recent studies have demonstrated that 
a splicing mutation in the STAR gene is a loss-of-function mutation that produces an aber-
rant protein [58]. Besides, non-sense-mediated mRNA decay (NMD), a conserved biological 
mechanism that degrades transcripts containing premature translation termination codons, 
could help secure the null effect when a DSB is induced in splice sites. In addition to transcripts 
derived from nonsense alleles, the substrates of the NMD pathway also include pre-mRNAs 
that enter the cytoplasm with introns intact [59]. Several mutations of splice donor sites that 
cause loss of gene function have recently been identified. A novel mutation at a splice donor 
site that was predicted to lead to skipping of exon 10 of the PLA2G6 gene was found in a homo-
zygous state in infantile neuroaxonal dystrophy patients. This variant was correlated with very 
strong loss of function, providing further evidence of its pathogenicity [60]. Mutations in the 
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ectodysplasin A1 gene (EDA-A1) at the splice donor site have been described in patients with 
hypohidrotic ectodermal dysplasia. The mutation resulted in the production of a truncated 
EDA-A1 protein caused by the complete omission of exon 3. This novel functional skipping-
splicing EDA mutation was considered to be the cause of the pathological phenotype [61]. 
Studies in a family with premature ovarian failure identified a variant that alters a splice donor 
site. This variant resulted in a predicted loss of function of the MCM9 gene, which is involved 
in homologous recombination and repair of double-stranded DNA breaks [62].
As we have mentioned before, not all indels targeting the exon coding sequences necessarily 
give rise to premature stop codons. However, if DSBs are induced near the boundaries of 
the target exon, then the canonical splicing pathway could also be altered. In that case, to 
the probability of producing frameshift, mutations should be added that of interfering with 
canonical pre-mRNA splicing (Figure 12B). Even if the CRISPR/Cas9-induced mutation did 
not produce a frameshift mutation, at least this strategy would offer the possibility of produc-
ing nonfunctional oncogenes by splice-pathway alteration. It has recently been shown that 
CRISPR/Cas9-mediated alterations at exon boundaries may also result in altered splicing of 
the respective pre-mRNA, most likely due to mutations of splice-regulatory sequences. Using 
the human FLOT-1 gene as an example, the authors demonstrated that such altered splicing 
products also give rise to aberrant protein products with loss of function [63].
An unpublished study has compared the efficiency of generating null alleles by CRISPR/Cas9 
sgRNAs targeting exon boundaries. The authors compared the efficiency of producing null 
alleles inducing DSBs in a central position of the critical exon with DSBs close to the splice 
donor site on the exon. The study, which was carried out in a variety of genes, species and 
systems, revealed an increase in knockout efficiency using sgRNA guides targeting the splice-
donor site of the chosen exon.
4. Conclusions
Genome-editing nucleases like the popular CRISPR/Cas9 enable knockout cell lines and 
null zygotes to be generated by inducing site-specific DSBs within a genome. In most cases, 
when a DNA template is not present, the DSB is repaired by nonhomologous end joining, 
Figure 12. CRISPR/Cas9 design against sequences involved in intron processing.
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resulting in small nucleotide insertions or deletions that can be used to construct knock-
out alleles. However, for several reasons, these mutations do not produce the desired null 
result in all cases, giving rise to a similar but functionally active protein. This undesirable 
effect could limit the therapeutic efficiency of gene therapy strategies that focus on abrogat-
ing oncogene expression by CRISPR/Cas9 and should be taken in account. The use of an 
sgRNA-targeting splicing site could improve the null result for in vivo gene therapies. This 
strategy could be adopted to abrogate in vivo the oncogenic activity involved in tumor 
maintenance.
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